Daphne Quimi Biography and Net Worth

Daphne Quimi began serving as a director of Amylyx in 2021. Ms. Quimi has more than 25 years of executive experience in the pharmaceutical and biotechnology industries with expertise in global finance operations, company building, and rare disease drug commercialization. She is a member of the Board of Directors at Century Therapeutics and Chiesi Group and most recently served as Chief Financial Officer (CFO) of Amicus Therapeutics. Ms. Quimi joined Amicus when it was a pre-commercial company and has the experience of helping build Amicus through its first regulatory approvals and launches for Galafold™ in the U.S., Europe, Canada and Japan. As CFO at Amicus, Ms. Quimi was responsible for directing all financial activities, including strategic planning, financial reporting and budgeting, investor relations and shareholder engagement. Prior to her roles at Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb and held roles of increasing responsibility in the finance division at Johnson & Johnson. She has also served as an auditor at KPMG. Ms. Quimi received a B.S. in Accountancy from Monmouth University in New Jersey and an MBA from the Stern School of Business of New York University.